Company Profile

Invitae Corporation is a medical genetics company. The Company is engaged in delivering genetic testing services, digital health solutions, and health data services that support a lifetime of patient care and improved outcomes. It offers genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases and pharmacogenomics. It applies proprietary design, process automation, robotics and bioinformatics software solutions to expand the use and impact of genetic information in sample processing and complex variant interpretation, allowing medical interpretation at scale. The Company also utilizes digital health solutions to improve ease-of-use and to deliver actionable information about risk, prevention, treatment, and monitoring. The Company has served over 3.6 million patients, and over 2.2 million of those patients have made their information available for data sharing.

Employees

1,700

Sector

Biotechnology & Medical Research

More about the company

Invitae Corporation Announces Cessation of Kenneth D. Knight as Chief Executive Officer	24-08-08	CI
Invitae Corporation Announces Cessation of Ana J. Schrank as Chief Financial Officer	24-08-08	CI
Invitae Corporation Announces Board and Executive Cessation	24-08-08	CI
Invitae Corporation Went Out of Business	24-08-07	CI
Labcorp Closes Buyout of Certain Invitae Assets	24-08-05	MT
Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Substantially all Assets of Invitae Corporation (OTCPK:NVTA.Q).	24-08-04	CI
Third Amended Joint Liquidation Plan Approved for Invitae Corporation	24-08-02	CI
Labcorp beats Q2 profit and revenue estimates on demand for health tests	24-08-01	RE
Third Amended Joint Liquidation Plan Filed by Invitae Corporation	24-08-01	CI
The trades that could bring down short-seller Andrew Left	24-07-26	RE
Invitae Launches Unlock Behind the Seizure Program for Pediatric Epilepsy Patients	24-07-22	CI
Second Amended Liquidation Plan Approved for Invitae Corporation	24-07-20	CI
Second Amended Joint Liquidation Plan Filed by Invitae Corporation	24-07-19	CI

Goldman Sachs Adjusts Price Target on Invitae to $0.50 From $1, Maintains Sell Rating	23-10-20	MT
Piper Sandler Trims Invitae Price Target to $0.50 From $1.50, Maintains Underweight Rating	23-08-15	MT
Goldman Sachs Adjusts Price Target on Invitae to $1 From $1.50, Maintains Sell Rating	23-07-21	MT
Piper Sandler Cuts Invitae's Price Target to $1.50 From $1.75, Maintains Underweight Rating	23-05-15	MT
Raymond James Downgrades Invitae to Underperform From Market Perform	23-05-15	MT

DELFI Diagnostics Names Robert Guigley as Chief Commercial Officer to Expand Access to Early Cancer Screening	24-10-30	AQ
Invitae : Bankruptcy Form 8 K	24-08-08	PU
Invitae : Regulation FD Presentation Form 8 K	24-07-01	PU
Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results	24-03-07	AQ
Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process	24-02-13	PR

Est-ce que la donne boursière est en train de changer ?	24-02-14
En Direct des Marchés : Capgemini, Alstom, Airbnb, Ahold, Sony, Nvidia, Walmart, Vicat...	24-02-14
EN DIRECTO DESDE LOS MERCADOS: Arcelormittal, BBVA, Santander, Mapfre, Iberdrola, Neinor Homes, ABN Sony, Heineken...	24-02-14
Bolsa de Madrid: ¿Está cambiando el mercado de valores?	24-02-14
La Chine a un plan (épisode 32)	24-02-06

Director	Title	Age	Since
Hoki Luk IRC	Investor Relations Contact	-	-
Robert Guigley PRN	Corporate Officer/Principal	-	2023-09-04

Invitae Corporation Stock

Equities

NVTA.Q

US46185L1035

Biotechnology & Medical Research

Chart: Invitae Corporation

Latest news: Invitae Corporation

Analysts' recommendations: Invitae Corporation

Press Releases: Invitae Corporation

News in other languages: Invitae Corporation

Managers and Directors: Invitae Corporation

ETFs: Invitae Corporation

Bio Diagnostics & Testing

Company Profile

Name	Weight	AuM	1st Jan change	Investor Rating
LEVERAGE SHARES -3X SHORTARKINNOVATION ETP SECURITIES - USD	0.63%	0 M€	0.00%	-
LEVERAGE SHARES 1X ARK GENOMIC TRACKER ETP - USD	0.57%	1 M€	0.00%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
EXACT SCIENCES CORPORATION	-1.39%	-6.63%	-19.50%	-36.19%	9.36B
VERACYTE, INC.	+4.10%	-0.46%	+62.04%	+40.76%	3.07B
BGI GENOMICS CO., LTD.	-0.60%	+9.91%	+13.38%	-41.03%	2.67B
IOVANCE BIOTHERAPEUTICS, INC.	+3.46%	-2.46%	-41.88%	-66.83%	1.63B
CAREDX, INC	-1.23%	+10.26%	+198.07%	-41.12%	1.33B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-3.35%	+5.48%	+109.90%	-43.63%	1.26B
SEEGENE, INC.	+1.10%	-5.75%	-10.53%	-56.12%	731M
MARAVAI LIFESCIENCES HOLDINGS, INC.	+3.88%	-7.10%	-17.38%	-85.75%	584M
VIMTA LABS LIMITED	+3.91%	+7.13%	+124.28%	+193.19%	276M
Average	+1.07%	-2.41%	+46.49%	-15.19%	2.32B
Weighted average by Cap.	+0.05%	-4.29%	+18.85%	-27.72%